September 9, 2025
A histopathology of lung cancer under a microscope.
Adobe

STAT+ | Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster

The drug, ivonescimab, produced weaker results in patients from North America and Europe than those from China.

By Adam Feuerstein

STAT+ | Biotech veteran Harvey Berger takes over as CEO of billionaire-backed Arena Bioworks

The research institute, which has said it has taken inspiration from the storied Bell Labs, has been experiencing a period of transition.

By Allison DeAngelis

A promising new treatment for a tough cancer

Today's health news covers a promising new treatment for a tough cancer, Florida vs. Trump vs. RFK Jr. vaccine requirements, etc.

By Theresa Gaffney

10 times STAT coverage reverberated through health and medicine

As STAT turns 10, a look at our milestone stories: Purdue Pharma secrets, UnitedHealth denials, hepatitis in prisons, Covid pandemic coverage, and more.

By STAT Staff
More around STAT

In case you missed it

  • Astrazeneca’s lung cancer combination boosted survival in key study, Bloomberg
  • Eli Lilly's blood cancer drug shows promise in trial as early treatment, Reuters
  • He started fighting wildfires as a teenager. After inhaling smoke on the front lines for six seasons, he faced an impossible choice, New York Times
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.
Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.
Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser